The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

Karl Pummer, Haro Stettner, Herbert Augustin, Richard Zigeuner, Helga Habermann, Luigi Schips, Ildiko Riedler, Harald Trummer, Kathrin Lipsky, Stephen Williams

Research output: Contribution to journalArticle

Abstract

Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p <0.001), clinical stage (p <0.001), prostatectomy grade (p <0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p <0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

Original languageEnglish (US)
Pages (from-to)489-494
Number of pages6
JournalOnkologie
Volume30
Issue number10
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Body Mass Index
Prostatectomy
Prostate-Specific Antigen
Counseling
Cohort Studies
Multivariate Analysis
Serum

Keywords

  • Body mass index
  • Prostate cancer
  • Prostatectomy, radical
  • Staging

ASJC Scopus subject areas

  • Oncology

Cite this

The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer. / Pummer, Karl; Stettner, Haro; Augustin, Herbert; Zigeuner, Richard; Habermann, Helga; Schips, Luigi; Riedler, Ildiko; Trummer, Harald; Lipsky, Kathrin; Williams, Stephen.

In: Onkologie, Vol. 30, No. 10, 10.2007, p. 489-494.

Research output: Contribution to journalArticle

Pummer, K, Stettner, H, Augustin, H, Zigeuner, R, Habermann, H, Schips, L, Riedler, I, Trummer, H, Lipsky, K & Williams, S 2007, 'The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer', Onkologie, vol. 30, no. 10, pp. 489-494. https://doi.org/10.1159/000106096
Pummer K, Stettner H, Augustin H, Zigeuner R, Habermann H, Schips L et al. The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer. Onkologie. 2007 Oct;30(10):489-494. https://doi.org/10.1159/000106096
Pummer, Karl ; Stettner, Haro ; Augustin, Herbert ; Zigeuner, Richard ; Habermann, Helga ; Schips, Luigi ; Riedler, Ildiko ; Trummer, Harald ; Lipsky, Kathrin ; Williams, Stephen. / The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer. In: Onkologie. 2007 ; Vol. 30, No. 10. pp. 489-494.
@article{3e7a55e468c64fd29067145399dd3d7a,
title = "The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer",
abstract = "Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p <0.001), clinical stage (p <0.001), prostatectomy grade (p <0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p <0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.",
keywords = "Body mass index, Prostate cancer, Prostatectomy, radical, Staging",
author = "Karl Pummer and Haro Stettner and Herbert Augustin and Richard Zigeuner and Helga Habermann and Luigi Schips and Ildiko Riedler and Harald Trummer and Kathrin Lipsky and Stephen Williams",
year = "2007",
month = "10",
doi = "10.1159/000106096",
language = "English (US)",
volume = "30",
pages = "489--494",
journal = "Oncology Research and Treatment",
issn = "2296-5270",
publisher = "S. Karger AG",
number = "10",

}

TY - JOUR

T1 - The use of body mass index to predict pathological stage in patients with clinically localized prostate cancer

AU - Pummer, Karl

AU - Stettner, Haro

AU - Augustin, Herbert

AU - Zigeuner, Richard

AU - Habermann, Helga

AU - Schips, Luigi

AU - Riedler, Ildiko

AU - Trummer, Harald

AU - Lipsky, Kathrin

AU - Williams, Stephen

PY - 2007/10

Y1 - 2007/10

N2 - Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p <0.001), clinical stage (p <0.001), prostatectomy grade (p <0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p <0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

AB - Background: To investigate whether body mass index (BMI) is an independent risk factor for nonorgan-confined disease in patients with clinically localized prostate cancer. Patients and Methods: Overall, 735 patients undergoing radical prostatectomy formed the study cohort. Pathological and clinical factors with special emphasis to BMI were used to determine a model for the prediction of nonorgan-confined disease. Results: 359 patients had pathologically nonorgan-confined prostate cancer. These patients showed a significantly higher BMI than those with organ-confined disease (26.7 vs. 26.2; p = 0.0012). In multivariate analysis, age (p = 0.049), prostate-specific antigen (PSA) (p <0.001), clinical stage (p <0.001), prostatectomy grade (p <0.001), and BMI (p = 0.004) were independent risk factors for nonorgan-confined disease. In patients with a serum PSA between 10.1 and 20 ng/ml only prostatectomy grade (p <0.001) and BMI (p = 0.005) remained independent predictors. Conclusion: Patients with nonorgan-confined disease showed a significantly higher BMI than those with organ-confined stages. Moreover, BMI was an independent predictor for nonorganconfined prostate cancer. This knowledge might be helpful in patient counseling to choose between various options for the treatment of clinically localized prostate cancer.

KW - Body mass index

KW - Prostate cancer

KW - Prostatectomy, radical

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=34648825499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648825499&partnerID=8YFLogxK

U2 - 10.1159/000106096

DO - 10.1159/000106096

M3 - Article

VL - 30

SP - 489

EP - 494

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

SN - 2296-5270

IS - 10

ER -